GlassScriptPhysician profile
Dianne E Wollaston
NPI 1427161637
$38,544.97
in general payments reported to CMS, 2019-2025
23 companies · $3,858 in 2025
The $3,858 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $1,638 · 2021: $3,847 · 2022: $1,125 · 2023: $1,635 · 2024: $6,304 · 2025: $3,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,800 · Food and Beverage: $3,873 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,800.00 |
| Food and Beverage | $3,872.58 |
| Education | $123.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $10,005.60 | 2019 | |
| Glaxosmithkline, LLC. | $9,453.45 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $5,098.41 | 2019-2025 | |
| Horizon Therapeutics Plc | $4,676.59 | 2019-2023 | Krystexxa |
| Amgen INC. | $2,363.97 | 2019-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $1,100.09 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $983.87 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $963.11 | 2019-2025 | |
| Lilly USA, LLC | $853.08 | 2019-2024 | Taltz |
| Janssen Biotech, INC. | $657.68 | 2019-2025 | Tremfya, Remicade, Stelara |
| Genzyme Corporation | $537.53 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $504.10 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $453.11 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $210.36 | 2019-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $142.92 | 2024-2025 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $125.01 | 2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $99.13 | 2020 | |
| Sanofi-Aventis U.S. LLC | $90.76 | 2019 | |
| Celgene Corporation | $83.86 | 2019 | |
| Medexus Pharma, INC. | $57.61 | 2019 | |
| Genentech USA, INC. | $42.93 | 2019 | |
| Mallinckrodt Enterprises LLC | $22.79 | 2019 | |
| Tersera Therapeutics LLC | $19.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dianne Wollaston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.